Match Better Cancer Treatments via Genomic BioMarkers Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Match Better Cancer Treatments via Genomic BioMarkers's estimated annual revenue is currently $4.8M per year.(i)
  • Match Better Cancer Treatments via Genomic BioMarkers's estimated revenue per employee is $155,000

Employee Data

  • Match Better Cancer Treatments via Genomic BioMarkers has 31 Employees.(i)
  • Match Better Cancer Treatments via Genomic BioMarkers grew their employee count by 7% last year.

Match Better Cancer Treatments via Genomic BioMarkers's People

NameTitleEmail/Phone
1
CHIEF MEDICAL ADVISOR & CO-FOUNDERReveal Email/Phone
2
VP Software Engineering / Software and Product DevelopmentReveal Email/Phone
3
VP OperationsReveal Email/Phone
4
DirectorReveal Email/Phone
5
Director Business DevelopmentReveal Email/Phone
6
Director EngineeringReveal Email/Phone
7
DIRECTOR OF SALESReveal Email/Phone
8
Director Clinical ReportingReveal Email/Phone
9
Associate Director Data Science, Head PawMatchReveal Email/Phone
10
Clinical Genomics Curation ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Match Better Cancer Treatments via Genomic BioMarkers?

CureMatch®, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch's PreciGENE® Decision Support System guides oncologists in the selection of cancer drugs customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options.

keywords:N/A

N/A

Total Funding

31

Number of Employees

$4.8M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Match Better Cancer Treatments via Genomic BioMarkers News

2022-04-20 - Genomic sequencing is changing diagnosis, treatment for patients ...

But far from suggesting that more treatment always leads to ... All patients underwent genomic sequencing using the UCSF500 Cancer Gene...

2022-04-19 - Oncology Times

New NCI-MATCH Treatment Arm Looks at dMMR & LAG-3-Positive Cancers ... the trial is open at more than 1,100 hospitals and cancer centers...

2022-04-13 - New blood stem cell road map helps scientists learn from mistakes ...

Below, we offer considerations for developing both complex genomic signature and single-gene biomarkers through clinical trial phases. In Phase...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.6M31N/AN/A
#2
$3.6M31N/AN/A
#3
$3.6M31N/AN/A
#4
$4.8M3111%N/A
#5
$2.4M31-6%$37M